Interventional Trials
|
A2aR
|
NCT02655822
|
Corvus
|
CPI-444
|
Phase 1/1b
|
single agent and in combination with Atezolizumab
|
allows prior PD-1/PD-L1
|
advanced solid malignancies
|
NCT02403193
|
Pablobio (Novartis)
|
PBF-509
|
Phase 1/1b
|
single agent and in combination PDR001 (anti-PD1)
|
allows prior PD-1/PD-L1
|
non-small cell lung cancer
|
NCT03099161
|
Merck
|
MK-3814
|
Phase 1
|
single agent and in combination with Pembrolizumab(anti-PD-1);
|
allows prior PD-1/PD-L1
|
advanced solid malignancies
|
NCT02740985
|
AstraZeneca
|
AZD4635
|
Phase 1
|
single agent and in combination with Durvalumab (anti-PDL-1)
|
allows prior PD-1/PD-L1
|
advanced solid malignancies
|
CD73
|
NCT02503774
|
Medimmune
|
MEDI9447
|
Phase 1
|
combination with Durvalumab (anti-PDL-1) (no single agent)
|
allows prior PD-1/PD-L1
|
advanced solid malignancies
|
NCT03267589
|
Medimmune
|
MEDI9447
|
Phase 2
|
single agent and in combination with Durvalumab (anti-PDL-1), Tremelilumab (anti-CTLA4), MEDI 0562 (anti-OX40)
|
allows prior PD-1/PD-L1
|
relapsed ovarian cancer
|
NCT02754141
|
Bristol-Meyers-Squibb
|
BMS-986179
|
Phase 1/2a
|
single agent and in combination with Nivolumab (anti-PD-1)
|
allows prior PD-1/PD-L1
|
advanced solid malignancies
|
Noninterventional Trialsa
|
CD39/CD73
|
NCT03255252
|
Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy
|
NCT02567929
|
Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patients With Breast Cancer
|